Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients Insights business of IMIDomics, a US-based biotechnology company focused on drug discovery for immune-mediated inflammatory diseases (IMIDs). The strategic acquisition provides UCB with direct access to one of the most advanced, deeply curated human datasets in immunology, significantly enhancing the company’s ability to accelerate therapeutic discovery and development.
“The acquisition of IMIDomics’ Patient Insight business represents a significant step in our strategy to build the most robust, human data–driven platform in immune mediated diseases,” said Alistair Henry, executive vice president & CSO at UCB. “IMIDomics has spent a decade assembling a dataset and network that are simply not replicable in today’s environment. Integrating these capabilities and highly skilled IMIDomics team and the insight they bring will elevate our ability to discover and develop medicines that are truly informed by patient biology.”
IMIDomics’ Patient Insight business, built on more than 18 years of clinical and molecular data generation, integrates epidemiological information, detailed clinical histories, imaging data, multi omic profiles, and longitudinal patient samples collected through a robust clinical network of more than 300 investigators and 130-plus recruiting centres. The business is powered by samples stored in the IMID Biobank at the Vall d’Hebron Institute of Research (VHIR) in Barcelona, one of the most comprehensive IMID-focused biobanks globally, with contributions from over 17,000 patients.
“With [UCB’s] scientific depth and commitment to innovation, we are confident the Patient Insight Engine will continue to unlock meaningful breakthroughs for people living with IMIDs,” said Professor Sara Marsal founder and CMO of IMIDomics.
Financial details of the agreement were not disclosed.
